<DOC>
	<DOCNO>NCT02497118</DOCNO>
	<brief_summary>This study mainly observe anti angiogenic drug Endostatin ( Endostar ) combine vinorelbine Cisplatin ( NP ) neoadjuvant therapy patient non small cell lung cancer clinical efficiency safety . Through anti angiogenesis therapy combine neoadjuvant chemotherapy improve treatment neoadjuvant therapy tumor response rate rate resection , At time , study anti angiogenesis therapy patient peripheral blood circulation endothelial cell ( CECs ) , level Endothelial progenitor cells（EPC） , micro vascular density（MVD） vascular endothelial growth factor ( VEGF ) expression level , understand correlation clinical efficacy anti angiogenesis therapy combine chemotherapy change marker . In order find reference basis prediction effect curative effect . The change blood volume , blood flow vascular permeability lung cancer treatment CT perfusion image study .</brief_summary>
	<brief_title>Recombinant Human Endostatin Combined With NP Neoadjuvant Chemotherapy Stage ⅢA NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>The pathology prove non small cell lung cancer ( must histologically ) . At present , patient ⅢA stage ( N2 ) evaluate assistant examination ; The patient evaluate image , laboratory examination examination ; Without chemotherapy anti angiogenic therapy ; There measure lesion Informed consent . Pregnant , lactate woman , patient fertility take contraceptive measure . Severe infection . Severe heart disease.Neuropsychiatric disorder , easy control . Severe diabetes . There obvious bleeding tendency . The 5 year history tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>lung cancer Anti angiogenesis therapy survival</keyword>
</DOC>